Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reldesemtiv Open-Label Extension in ALS (CY 5032)
NCT05442775Phase 3Terminated
- Sponsor
- Cytokinetics
- Start
- Aug 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of reldesemtiv in amyotrophic lateral sclerosis (ALS), sponsored by Cytokinetics. Started Aug 2022; status: terminated.
02
Drugs
reldesemtiv
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05442775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05442775.